Performance and Cost Efficiency of KRAS Mutation Testing for Metastatic Colorectal Cancer in Routine Diagnosis: The MOKAECM Study, a Nationwide Experience

PURPOSE: Rapid advances in the understanding of cancer biology have transformed drug development thus leading to the approval of targeted therapies and to the development of molecular tests to select patients that will respond to treatments. KRAS status has emerged as a negative predictor of clinica...

Descripción completa

Detalles Bibliográficos
Autores principales: Blons, Hélène, Rouleau, Etienne, Charrier, Nathanaël, Chatellier, Gilles, Côté, Jean-François, Pages, Jean-Christophe, de Fraipont, Florence, Boyer, Jean-Christophe, Merlio, Jean Philippe, Morel, Alain, Gorisse, Marie-Claude, de Cremoux, Patricia, Leroy, Karen, Milano, Gérard, Ouafik, L’Houcine, Merlin, Jean-Louis, Le Corre, Delphine, Aucouturier, Pascaline, Sabourin, Jean-Christophe, Nowak, Frédérique, Frebourg, Thierry, Emile, Jean-François, Durand-Zaleski, Isabelle, Laurent-Puig, Pierre
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2013
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3723748/
https://www.ncbi.nlm.nih.gov/pubmed/23935912
http://dx.doi.org/10.1371/journal.pone.0068945

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3723748/
https://www.ncbi.nlm.nih.gov/pubmed/23935912
http://dx.doi.org/10.1371/journal.pone.0068945

Ejemplares similares